These results validate MGMT-Net as a unified, non-invasive framework for accurate glioma molecular biomarker prediction, offering a tissue-based diagnostic alternative in clinical scenarios where biopsy is contraindicated or poses a significant risk. Here, MGMT is linked to central nervous system cancer.